EOS-984 is a potential first-in-class small molecule in oncology inhibiting ENT1 that we are developing to reverse suppression of the immune system’s response and restore T cell proliferation in the tumor microenvironment. ENT1 is a dominant transporter of extracellular adenosine on T cells in the tumor which allows adenosine entry into the cell, disturbing T cell metabolism, expansion, effector function, and survival.

We have designed EOS-984 to block the transport of adenosine into the T cell through the ENT1, restoring T cell expansion and tumor-cell killing activity.